Highlights

Favipiravir, an RNA-dependent RNA polymerase inhibitor, shows no benefit in preventing the hospitalization of mild to moderate COVID-19 patients.
Our results may inform decisions on the exclusion of Favipiravir from mild to moderate COVID-19 treatment guidelines.